Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia.
BloodSep 24, 2026
Xiaoyuan Gong, Yuntao Liu, Qiuyun Fang et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II multicenter trial evaluated the efficacy of venetoclax combined with pediatric-inspired chemotherapy in 167 adolescents and adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL). The study found a complete remission rate of 91.0%, with 73.0% of responders achieving measurable residual disease negativity, indicating improved outcomes with this treatment approach.
Key findings
- Complete remission rate was 91.0% in the study population.
- 73.0% of responders achieved measurable residual disease negativity after induction.
- Estimated 2-year overall survival rate was 78.5%.
Why it matters
The findings suggest that incorporating venetoclax into first-line therapy for newly diagnosed Ph- ALL may enhance treatment efficacy, particularly in achieving measurable residual disease negativity, which is crucial for long-term outcomes.